Steve Lenier

Steve Lenier

Contributing Writer

Steve Lenier began a career in medical literature over 30 years ago. He has worked on a variety of publications and projects, and across a number of specialties. Since 2005 most of his time has been spent covering ophthalmology, both print and online.

  • All
  • Deals
  • Devices and Diagnostics
  • Digital
  • Genetics
  • Pharma
AbbVie Regroups after FDA Issues Complete Response Letter Rejecting Abicipar Pegol

July 9 2020

AbbVie Regroups after FDA Issues Complete Response Letter Rejecting Abicipar Pegol

Weeks after completing its acquisition of Allergan, AbbVie is seeking a meeting with the US Food and Drug Administration to talk about the next steps ...
Read More
Necessity Is the Mother of Collaborative Care between Optometrists and Ophthalmologists

June 17 2020

Necessity Is the Mother of Collaborative Care between Optometrists and Ophthalmologists

Collaborative care models – optometrists and ophthalmologists working together on patient care – are emerging as a way to reduce some of the strain caused ...
Read More
AbbVie’s Big Bet to Diversify with Allergan Pays Off So Far

May 20 2020

AbbVie’s Big Bet to Diversify with Allergan Pays Off So Far

Now that it has closed on its $63 billion acquisition of Allergan, AbbVie has significantly expanded its revenue base, which could help cushion the blow ...
Read More
Eyenuk’s EyeArt AI System Showing Its Value

May 13 2020

Eyenuk’s EyeArt AI System Showing Its Value

Eyenuk Inc.’s first product, the EyeArt AI eye screening system, is an artificial intelligence (AI) technology for autonomous detection of diabetic retinopathy that’s been tested ...
Read More
With Fresh Funding, Eyenovia Pursues Platform for Focused Drug Delivery

April 29 2020

With Fresh Funding, Eyenovia Pursues Platform for Focused Drug Delivery

Developing a delivery system to replace eye drops has been an important unmet need in ophthalmology. Drops are difficult or impossible for some patients to ...
Read More
Adverum, Gene Therapy, and AMD

March 25 2020

Adverum, Gene Therapy, and AMD

Adverum, a company pioneering novel gene therapies for ocular diseases, believes a gene therapy treatment for wet age-related macular degeneration (AMD) can reduce treatment burden ...
Read More
Innovations a Highlight at Dry Eye Breakout Session

January 8 2020

Innovations a Highlight at Dry Eye Breakout Session

The dry eye disease (DED) market is expected to have an annual compound growth rate of 4.5% between 2017 and 2025, which should help it ...
Read More
BioGenware’s Speculet Seeks to Improve the Patient Experience

December 18 2019

BioGenware’s Speculet Seeks to Improve the Patient Experience

For those undergoing intravitreal injections (and there are about 22 million of these performed yearly worldwide), a common complaint is that the speculum is uncomfortable, ...
Read More
Bausch, Clearside See Gains Post-Deal

November 20 2019

Bausch, Clearside See Gains Post-Deal

When it comes to the stock market, Bausch Health’s has been rising steadily, up 4.1% in the past month, and on November 13 hit a ...
Read More
Private Financing Trends: Ophthalmology Ranks Tenth

November 7 2019

Private Financing Trends: Ophthalmology Ranks Tenth

SAN FRANCISCO, Calif. — Almost $25 billion in venture funds have been raised in just the United States alone over the past 2.5 years to ...
Read More
Ain’t Misbehaving

October 23 2019

Ain’t Misbehaving

What a difference a day (or so) makes. On Oct. 10, the day of the Ophthalmic Innovation Summit, Aerie Pharmaceuticals' stock closed at $17.72. The ...
Read More
What Has 50 Companies, Four Breakout Sessions, Winning Pitch Winners, and a Keynote Conversation? OIS@AAO 2019

September 25 2019

What Has 50 Companies, Four Breakout Sessions, Winning Pitch Winners, and a Keynote Conversation? OIS@AAO 2019

SAN FRANCISCO — Winners of a “Shark Tank” style challenge in cataract/refractive and retina and specialty showcase sessions targeting four themes, including gene and cell ...
Read More